相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Class IA Phosphatidylinositol 3-Kinase Inhibition Inhibits Cell Growth and Proliferation in Mantle Cell Lymphoma
Yoko Tabe et al.
ACTA HAEMATOLOGICA (2014)
Putative Roles for PI3K alpha and delta Isoforms in Refractory Mantle Cell Lymphoma
Katti A. Jessen et al.
ACTA HAEMATOLOGICA (2014)
A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)
Brad S. Kahl et al.
BLOOD (2014)
Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells
Jiao Ma et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma
James S. Blachly et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
New Paradigms in Mantle Cell Lymphoma: Is It Time to Risk-Stratify Treatment Based on the Proliferative Signature?
Martin Dreyling et al.
CLINICAL CANCER RESEARCH (2014)
Discovery of 8-Cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a Potent Inhibitor of Cyclin-Dependent Kinase 4 (CDK4) and AMPK-Related Kinase 5 (ARKS)
M. V. Ramana Reddy et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Preclinical Pharmacological Evaluation of a Novel Multiple Kinase Inhibitor, ON123300, in Brain Tumor Models
Xiaoping Zhang et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Pharmacological and genomic profiling identifies NF-kappa B-targeted treatment strategies for mantle cell lymphoma
Rami Rahal et al.
NATURE MEDICINE (2014)
Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma
David Chiron et al.
CANCER DISCOVERY (2014)
Integrated Pharmacokinetic-Driven Approach to Screen Candidate Anticancer Drugs for Brain Tumor Chemotherapy
Hua Lv et al.
AAPS JOURNAL (2013)
P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse
Sunil Iyengar et al.
BLOOD (2013)
Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1
David Chiron et al.
CELL CYCLE (2013)
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
LYMPHOID NEOPLASIA Taking it up a notch in MCL
Samir Parekh
BLOOD (2012)
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
John P. Leonard et al.
BLOOD (2012)
Akt, FoxO and regulation of apoptosis
Xinbo Zhang et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2011)
New molecular targets in mantle cell lymphoma
Samir Parekh et al.
SEMINARS IN CANCER BIOLOGY (2011)
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
R. Eric Davis et al.
NATURE (2010)
The PI3K Isoforms p110α and p110δ Are Essential for Pre-B Cell Receptor Signaling and B Cell Development
Faruk Ramadani et al.
SCIENCE SIGNALING (2010)
Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma
Jessica Dal Col et al.
BLOOD (2008)
Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma
Martina Rudelius et al.
BLOOD (2006)
Cyclin-dependent kinase pathways as targets for cancer treatment
GI Shapiro
JOURNAL OF CLINICAL ONCOLOGY (2006)
Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity
Michal Marzec et al.
BLOOD (2006)
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
DD Sarbassov et al.
SCIENCE (2005)
ARK5 is a tumor invasion-associated factor downstream of Akt signaling
A Suzuki et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
FKBP12-rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions
RT Peterson et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
分享论文
